Drug Profile
DFP 13318
Alternative Names: DFP-13318; PEG-SN-38; PEG-SN-38 conjugates - Prolynx; Pegylated SN-38 conjugate PLX038; Pegylated SN-38 PLX038; PLX 264; PLX-0264; PLX-038; Polyethylene-glycol-SN 38-conjugates - ProLynxLatest Information Update: 02 Apr 2024
Price :
$50
*
At a glance
- Originator Prolynx
- Developer Curie Institute; Delta-Fly Pharma; National Cancer Institute (USA); Prolynx
- Class Alkaloids; Antineoplastics; Camptothecins; Drug conjugates; Polyethylenes; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Ovarian cancer; Triple negative breast cancer
- Phase I/II CNS cancer; Small cell lung cancer
- No development reported Solid tumours
Most Recent Events
- 29 Mar 2024 Curie Institute plans a phase I trial for Solid tumors (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in France (IV) in June 2024 (NCT06337630)
- 25 Mar 2024 Phase-II clinical trials in Triple-negative-breast-cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in France (IV) (NCT06162351)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in USA (IV, Infusion)